By Tess Stynes
Pfizer Inc. on Wednesday said a late-stage study of its Ibrance
breast-cancer drug in combination with fulvestrant was stopped
early after meeting its primary endpoint of demonstrating
improvement in progression-free survival.
The pharmaceutical company said the decision to halt the study
was based on an assessment by an independent data-monitoring
committee.
Shares of Pfizer, up 17% over the past year, rose 1.8% in
premarket trading.
Ibrance, also known as palbociclib, received accelerated
approval from the U.S. Food and Drug Administration in February as
a first-line treatment for women with a certain type of advanced or
metastatic breast cancer.
Pfizer said it is in discussions with health regulators
regarding a path for approval of Ibrance in combination with
fulvestrant.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for Pfizer Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US7170811035
Subscribe to WSJ: http://online.wsj.com?mod=djnwires